Drug Profile
Research programme: cytomegalovirus DNA vaccines - Fresh Tracks Therapeutics/Virginia Commonwealth University
Alternative Names: CMV vaccineLatest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Vical; Virginia Commonwealth University
- Developer Fresh Tracks Therapeutics
- Class Protein vaccines; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Cytomegalovirus infections (Prevention) in USA (Parenteral)
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary